Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-09 |
2024-03 |
-2.88 |
-2.83 |
0.05 |
1.74% |
2024-03-07 |
2023-12 |
-3.09 |
-3.11 |
-0.02 |
-0.65% |
2023-11-09 |
2023-09 |
-3 |
-3.4 |
-0.4 |
-13.33% |
2023-08-10 |
2023-06 |
-3.4 |
-3 |
0.4 |
11.76% |
2023-05-04 |
2023-03 |
-4.2 |
-4 |
0.2 |
4.76% |
2023-03-09 |
2022-12 |
-4.4 |
-4 |
0.4 |
9.09% |
Date |
Firm |
Action |
From |
To |
2023-09-17 |
HC Wainwright & Co. |
Upgrade |
Neutral |
Buy |
2023-09-06 |
Cantor Fitzgerald |
Upgrade |
Neutral |
Neutral |
2023-06-05 |
HC Wainwright & Co. |
Upgrade |
|
Neutral |
2023-04-03 |
Maxim Group |
Downgrade |
Buy |
Hold |
2023-04-03 |
Brookline Capital |
Downgrade |
Buy |
Hold |
2023-04-03 |
Cantor Fitzgerald |
Upgrade |
|
Overweight |
Date |
Name |
Relation |
Quantity |
Description |
2020-07-20 |
AKER HAZEL MARIE |
General Counsel |
0.00 |
Purchase |
2023-04-13 |
BREITMEYER JAMES B |
Chief Executive Officer |
0.00 |
Purchase |
2020-08-31 |
CARTER MICHAEL GREENWOOD |
Director |
71.95K |
Purchase |
2021-09-30 |
HALE DAVID F |
Director |
0.00 |
Stock Gift |
2023-06-13 |
KAUFMANN GUNNAR F |
Officer |
94.73K |
Purchase |
2020-07-20 |
KISNER DANIEL L |
Director |
0.00 |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Group Inc |
2.86M |
987.01K |
4.85% |
2023-06-29 |
Millennium Management Llc |
1.64M |
567.48K |
2.79% |
2023-06-29 |
Blackrock Inc. |
785.91K |
271.14K |
1.33% |
2023-06-29 |
Kennedy Capital Management, Inc. |
587.37K |
202.64K |
1.00% |
2023-06-29 |
Quantum Private Wealth, LLC |
456.19K |
157.38K |
0.77% |
2023-06-29 |
Geode Capital Management, LLC |
415.58K |
143.38K |
0.70% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
2.16M |
745.13K |
3.66% |
2023-06-29 |
Vanguard Extended Market Index Fund |
621.23K |
214.33K |
1.05% |
2023-05-30 |
Fidelity Extended Market Index Fund |
218.36K |
62.23K |
0.37% |
2023-05-30 |
Fidelity Total Market Index Fund |
80.55K |
22.96K |
0.14% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
60.39K |
17.21K |
0.10% |
2023-06-29 |
Vanguard Institutional Index-Inst Total Stock Market Ind |
34.03K |
11.74K |
0.06% |
Split |
Date |
1 : 20 |
2024-01-08 |
1 : 7 |
2019-06-10 |
1 : 10 |
2016-12-06 |